Passage Bio Reports Promising Q2 2025 Financial Results

An update from Passage Bio ( (PASG) ) is now available.

On August 12, 2025, Passage Bio reported its second quarter financial results and business highlights, including the completion of dosing for Cohort 2 in the upliFT-D study and submission of an amended study protocol. The company demonstrated promising interim data for PBFT02, showing significant elevation in cerebrospinal fluid progranulin levels and improvement in disease biomarkers, which could enhance its position in the neurodegenerative disease treatment market. Passage Bio maintains a cash runway into the first quarter of 2027, indicating financial stability to support ongoing and future clinical trials.

The most recent analyst rating on (PASG) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Passage Bio stock, see the PASG Stock Forecast page.

Spark’s Take on PASG Stock

According to Spark, TipRanks’ AI Analyst, PASG is a Neutral.

Passage Bio scores moderately low due to its financial challenges, including no revenue and significant cash burn. However, a strong balance sheet and recent corporate event announcements, including program advancements and extended cash runway, provide some optimism. Technical indicators suggest a neutral to bearish sentiment, and traditional valuation metrics are limited due to the company’s stage and lack of profitability.

To see Spark’s full report on PASG stock, click here.

More about Passage Bio

Passage Bio is a clinical stage genetic medicines company focused on developing therapies for neurodegenerative diseases. The company’s lead product candidate, PBFT02, aims to treat conditions such as frontotemporal dementia by elevating progranulin levels to restore lysosomal function and slow disease progression.

Average Trading Volume: 47,043

Technical Sentiment Signal: Sell

Current Market Cap: $18.41M

Find detailed analytics on PASG stock on TipRanks’ Stock Analysis page.